Ben M'rad Mona, Leclerc-Mercier Stéphanie, Blanche Philippe, Franck Nathalie, Rozenberg Flore, Fulla Yvonne, Guesmi Myriam, Rollot Florence, Dehoux Monique, Guillevin Loïc, Moachon Laurence
From the Department of Internal Medicine, Reference Center for Autoimmune and Inflammatory Diseases: Necrotizing Vasculitides and Systemic Sclerosis (MB, PB, F Rollot, LG), Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University (MB, SL, F Rozenberg, YF, MG, LG, LM), Paris; Department of Dermatology (SL, NF), Department of Virology (F Rozenberg), Department of Biophysics (YF), and Department of Radiology (MG), Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris; Department of Biochemistry (MD), Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris; and Regional Pharmacovigilance Center and Department of Pharmacology (LM), Assistance Publique-Hôpitaux de Paris, Paris, France.
Medicine (Baltimore). 2009 May;88(3):131-140. doi: 10.1097/MD.0b013e3181a4d1a1.
Drug-induced hypersensitivity syndrome (DIHS), also called drug rash with eosinophilia and systemic symptoms (DRESS), is a severe reaction usually characterized by fever, rash, and multiorgan failure, occurring 1-8 weeks after drug introduction. It is an immune-mediated reaction involving macrophage and T-lymphocyte activation and cytokine release, although no consensus has been reached as to its etiology. The skin, hematopoietic system, and liver are frequently involved. DIHS can mimic severe sepsis, viral infection, adult-onset Still disease (AOSD), or lymphoproliferation.We describe 24 consecutive patients with DIHS who were hospitalized between September 2004 and March 2008. Criteria for inclusion in this observational study were suspected drug reaction, eosinophilia >or=500/microL and/or atypical lymphocytes, involvement of at least 2 organs (skin being 1 of them), with suggestive chronology and exclusion of other diagnoses. Our cohort of 12 women and 12 men had a median age of 49 years (range, 22-82 yr), and 11 had skin phototype V or VI. Patients with mild or no rash were immunocompromised (7/24)- defined as treatment with prednisone (>or=10 mg/d) and another immunosuppressant drug, or human immunodeficiency virus infection. All patients were febrile (>38 degrees C), 14 had localized or generalized edema, 7 had pharyngitis, 8 had lymphadenopathy, 22 had hepatitis, 4 had nephritis, 2 had noninfectious and nonlithiasic angiocholitis or cholecystitis. Ten patients were hypotensive, 5 of whom had associated laboratory signs and/or imaging findings suggestive of acute myocardial dysfunction. Half of the patients had hemogram abnormalities, including eosinophilia. Nine DIHS patients fulfilled the Fautrel criteria for AOSD diagnosis, including glycosylated ferritin <20% in 4/11, with or without laboratory characteristics of hemophagocytosis. Twenty DIHS episodes occurred during the less sunny months of October to March.We determined 25-hydroxyvitamin D3 (25[OH]D3) levels in 18 patients and found that 9 patients had vitamin D deficiency (<25 nmol/L or <10 microg/L) and 5 had vitamin D insufficiency (25-50 nmol/L). Moreover, 25(OH)D3 levels were inversely correlated with ferritin values. After culprit-drug withdrawal, outcomes were favorable for all patients, including those with cardiac abnormalities under slow tapering of glucocorticoids.We recommend looking for the frequent but underdiagnosed hypersensitivity myocarditis with noninvasive diagnostic tools, such as N-terminal probrain natriuretic peptide, and promptly withdrawing the culprit drug and starting glucocorticoids. Vitamin D deficiency might be a DIHS risk or severity factor, especially for patients with high skin phototype and during the winter. Because DIHS clinical and laboratory patterns share similarities with AOSD and hemophagocytosis, DIHS should be included in their differential diagnoses.
药物性超敏反应综合征(DIHS),也称为伴有嗜酸性粒细胞增多和全身症状的药疹(DRESS),是一种严重反应,通常表现为发热、皮疹和多器官功能衰竭,在用药后1 - 8周出现。这是一种免疫介导的反应,涉及巨噬细胞和T淋巴细胞激活以及细胞因子释放,尽管其病因尚未达成共识。皮肤、造血系统和肝脏常受累。DIHS可类似严重脓毒症、病毒感染、成人斯蒂尔病(AOSD)或淋巴增殖性疾病。我们描述了2004年9月至2008年3月期间连续住院的24例DIHS患者。本观察性研究的纳入标准为疑似药物反应、嗜酸性粒细胞增多≥500/μL和/或非典型淋巴细胞、至少累及2个器官(其中之一为皮肤),具有提示性的发病时间顺序且排除其他诊断。我们的队列中有12名女性和12名男性,中位年龄为49岁(范围22 - 82岁),11人皮肤光类型为V型或VI型。皮疹轻微或无皮疹的患者存在免疫功能低下(7/24)——定义为接受泼尼松(≥10 mg/d)和另一种免疫抑制药物治疗,或感染人类免疫缺陷病毒。所有患者均发热(>38℃),14人有局部或全身性水肿,7人有咽炎,8人有淋巴结病,22人有肝炎,4人有肾炎,2人有非感染性和非结石性胆管炎或胆囊炎。10名患者有低血压,其中5人伴有提示急性心肌功能障碍的实验室指标和/或影像学表现。一半患者有血常规异常,包括嗜酸性粒细胞增多。9例DIHS患者符合AOSD诊断的Fautrel标准,其中4/11患者糖化铁蛋白<20%,伴或不伴有噬血细胞增多的实验室特征。20例DIHS发作发生在10月至3月阳光较少的月份。我们测定了18例患者的25 - 羟维生素D3(25[OH]D3)水平,发现9例患者维生素D缺乏(<25 nmol/L或<10 μg/L),5例患者维生素D不足(25 - 50 nmol/L)。此外,25(OH)D3水平与铁蛋白值呈负相关。停用可疑药物后,所有患者预后良好,包括那些在糖皮质激素缓慢减量过程中出现心脏异常的患者。我们建议使用无创诊断工具,如N末端脑钠肽前体,寻找常见但诊断不足的过敏性心肌炎,并迅速停用可疑药物并开始使用糖皮质激素。维生素D缺乏可能是DIHS的一个风险或严重程度因素,特别是对于皮肤光类型高的患者以及在冬季。由于DIHS的临床和实验室模式与AOSD和噬血细胞增多症有相似之处,DIHS应纳入其鉴别诊断。